The added value of quantitative analysis of on-therapy impedance-pH parameters in distinguishing refractory non-erosive reflux disease from functional heartburn

Neurogastroenterology and Motility

Volumn 24, Issue 2, 2012, Pages

  Frazzoni, M ^a   Conigliaro, R ^a   Mirante, V G ^a   Melotti, G ^a  

^a Nuovo Ospedale S Agostino   (Italy)

Author keywords

Functional heartburn; Impedance pH monitoring; Non acid reflux; Non erosive reflux disease; Refractory gastro esophageal reflux disease; Weakly acidic reflux

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; ESOPHAGEAL PH MONITORING; FEMALE; GASTROSCOPY; HEARTBURN; HIATUS HERNIA; HUMAN; IMPEDANCE; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MANOMETRY; NON EROSIVE REFLUX DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REFRACTORY PERIOD; TIME;

ADULT; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL PH MONITORING; ESOPHAGITIS, PEPTIC; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84855940310     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01800.x     Document Type: Article

References (32)

1. Bredenoord AJ. Impedance-pH monitoring: new standard for measuring gastro-oesophageal reflux. Neurogastroenterol Motil 2008; 20: 434-9.
2. Vakil N, van Zanten SV, Kahrilas P, the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
3. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
4. Hershcovici T, Fass R. Nonerosive reflux disease (NERD) - an update. J Neurogastroenterol Motil 2010; 16: 8-21.
5. Kahrilas PJ, Smout AJPM. Esophageal disorders. Am J Gastroenterol 2010; 105: 747-56.
6. Mainie I, Tutuian R, Shay S et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55: 1398-402.
7. Zerbib F, Roman S, Ropert A et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101: 1956-63.
8. Sharma N, Agrawal A, Freeman J, Vela M, Castell DO. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6: 521-4.
9. Hemmink GJM, Bredenoord AJ, Weusten BLAM, Monkelbaan JF, Timmer M, Smout AJPM. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: "on" or "off" proton pump inhibitor? Am J Gastroenterol 2008; 103: 2446-53.
10. Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG, Vaezi MF. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009; 7: 743-8.
11. Pandolfino JE, Vela MF. Esophageal-reflux monitoring. Gastrointest Endosc 2009; 69: 917-30.
12. Blondeau K, Tack J. Pro: impedance testing is useful in the management of GERD. Am J Gastroenterol 2009; 104: 2664-6.
13. Zerbib F, Bruley Des Varannes S, Roman S et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 2005; 22: 1011-21.
14. Frazzoni M, Savarino E, Manno M et al. Reflux patterns in patients with short segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy. Aliment Pharmacol Ther 2009; 30: 508-15.
15. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
16. Frazzoni M, Grisendi A, Lanzani A, Melotti G, De Micheli E. Laparoscopic fundoplication versus lansoprazole for gastro-esophageal reflux disease. A pH-metric comparison. Dig Liver Dis, 2002; 34: 99-104.
17. Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut 2001; 49: 145-51.
18. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53: 1024-31.
19. Frazzoni M, Conigliaro R, Melotti G. Reflux parameters as modified by laparoscopic fundoplication in 40 patients with heartburn/regurgitation persisting despite PPI therapy. A study using impedance-pH monitoring. Dig Dis Sci 2011; 56: 1099-106.
20. Frazzoni M, De Micheli E, Zentilin P, Savarino V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004; 20: 81-8.
21. Savarino E, Gemignani L, Pohl D et al. Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 34: 476-86.
22. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91.
23. Spechler JS. Surgery for gastroesophageal reflux disease: esophageal impedance to progress? Clin Gastroenterol Hepatol 2009; 7: 1264-5.
24. Dellon ES, Shaheen NJ. Persistent reflux symptoms in the proton pump inhibitor era: the changing face of gastroesophageal reflux disease. Gastroenterology 2010; 139: 7-13.
25. Vaezi MF. Reflux monitoring: on or off therapy?. Am J Gastroenterol 2011; 106: 183-5.
26. Savarino E, Marabotto E, Zentilin P et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis 2011; 43: 542-7.
27. Shay S, Tutuian R, Sifrim D et al. Twenty-four hour ambulatory simultaneous impedance and pH-monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004; 99: 1037-43.
28. Zentilin P, Iiritano E, Dulbecco P et al. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Dig Liver Dis 2006; 38: 226-32.
29. Savarino E, Tutuian R, Zentilin P et al. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and non-erosive reflux disease: study using combined impedance-pH off therapy. Am J Gastroenterol 2010; 105: 1053-61.
30. Agrawal A, Roberts J, Sharma N, Tutuian R, Vela M, Castell DO. Symptoms with acid and nonacid reflux may be produced by different mechanisms. Dis Esophagus 2009; 22: 467-70.
31. Aanen MC, Bredenoord AJ, Numans ME, Samson M, Smout AJPM. Reproducibility of symptom association analysis in ambulatory reflux monitoring. Am J Gastroenterol 2008; 103: 2200-8.
32. Bredenoord AJ, Weusten BLAM, Smout AJPM. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut 2005; 54: 1810-7.